Member Info for RuckRover

GF,
“ Ruck. May I suggest you read loz’s posts then.”
You may and I have. Not sure where that gets us. ATB

GF,
NXC makes the very occasional, considered and factual comment. These are to be welcomed and considered. The fact he had retained, and added to his very considerable holding should be some reassurance to other shareholders. No one calls anyone a tyHyper for building a holding of any size, it’s the wild, factually inaccurate, misleading claims that attract those sort of labels.
There’s enough potential and upside here without having to over egg the pudding.

Douve,
I echo C7’s comments - your views are most welcome and certainly add much to the debate.
When I made my comment about a £2M deal versus a £33M fund raise, I hadn’t even considered the dilution aspect. Although you get a smaller slice of the cake, surely the cake just got a whole lot bigger? Isn’t this the case with all dilutive funding - we hope that our smaller share will be of a larger cake or at least there actually will be some cake!
Regarding Scanecell’s deal negotiations, Bermuda made a good analogy on ADVFN ....
“ It's a bit like selling a house when you've only got as far as the foundations.”
You would hope that any buyer could see the value in the plot and examine the plans but the finished product is much more likely to entice - the kitchen and bathroom, the quality of the finish, the view from the master bedroom - where do I sign?
Overall, I can only see good news in yesterday’s announcement, that’s just my personal opinion.

Knowlesi,
Im not at all disappointed in the SCIB2 news. CRUK have made no progress in 3 years. When asked about this, the BOD said it is out of there hands. Now it is back in their hands.
Plus, the TD formula said 15% royalties to Scancell. I can now up this to 17.5% in my algorithm. That’s got to worth a penny on the SP!

Chester,
There is a bigger game being played it’s just that we don’t know the final score.
It’s rather bizarre that had the RNS said we had concluded a deal with a £2M upfront payment, many would have been ecstatic. But an RNS saying we had an extra £33M draws disappointment from some quarters!

I agree, there is a danger of over-analysing.

“With the additional funds available from the Capital Raise, the Company intends to add further value to both the Avidimab™ platform and the TaG antibodies before concluding any licensing deals."

This is quite clear and straightforward. The communication from the last fund raise was that we had enough funds to see SCIB1 and MODI1 through clinical trials. This would be supplemented by selling off some Early stage mabs.
Now, it appears that with the additional funding, there is no necessity to flog the family jewels cheap and their value will be enhanced before doing a deal.
So, no deal will be forthcoming imminently but this is a positive thing, not negative.

Botski,
“Imagine if I told the Knowlesi of 2019 that Scancell would be at 17.5p and have £45 Million in the bank, you would have laughed me out of town.”

It cuts both ways...
Imagine if I told the Botski of 2012 that Scancell would be at 17.5p and have £45 Million in the bank, you would have laughed me out of town.

C7,
The placing/OO raised £14M net of expenses as Stakis says.
The Gov grant was £2M to Scancell (the other £.7M went to Nottingham Uni collaboration.
You may have over-estimated the cash in hand.
You may well be underestimating the cash burn (as Stakis is alluding to)

I notice the old “lifestyle” jibe has been taken from the closet and used to flagellate certain poster(s).
So while we are quiet, here’s my twopence. Feel free to ignore!
We shouldn’t use the term “lifestyle” in a derogatory or negative way. It does not necessarily mean a family business working from a small kitchen churning out bottles of sauce or whatever. The term lifestyle may be applied to the founders of the business but this does not mean it can’t become a multi-million pound enterprise. It simply means that the founder(s) have personal objectives aside from making investors and venture capitalists rich.
I think this IS the case with professor Durrant. She has chose the quest to cure cancer and continue in her Nottingham university post above the scramble for riches.
The situation with Scancell is more complex. In her quest to find cures for an increasing number of cancers, the company does become more scalable - the more cancers, the more potential for financial gain. Whilst not Durrants’s primary motive, it is a side effect not missed by some big institutional investors. Long may her chosen “lifestyle” continue!

Knowlesi,

A week or so back I said..
“Knowlesi,
Surely you have to agree that there is less risk now at 18p than there was 8 years ago at 45p?
Increased IP, more cash to play with AND a lower entry price - what’s not to like? :)”
So investing some of the cash raised in people who can actually add to the IP and progress the monetisation of those assets surely has to be a positive move?
I am all for balance but I feel the pendulum has swung too far the other way and smacked you on the head.

Ray, my thoughts exactly - you beat me to it!

Evening C7,
You missed one!
ATB.

"Must be able to work to tight deadlines" lol... are we sure this is a Scancell ad ;)
It says “work to” not “meet them”

Hi C7,

I meant mentally and physically but I can throw in spiritually as well if you like.

There's no point looking back and having regrets about buying/not buying at 6p. You have to focus on what happens from here. I think 16p is still good value given the pipeline and timescales (even with slippage!) I did buy a few today - you may have noticed :) Remember, it's the number you hold that is important.

There will be anticipation, speculation, expectation, hope and excitement in the lead up to results and the results themselves. I expect the SP to nudge up over the course of the days leading up to it. If there is no new news we will then slip back, if there is reasonable news we may hold position if there is great news we could rocket. Don't forget, Trinity Delta have a value of 74p per share on just SCIB1, SCIB2 and MODI1 being successful. Steady progress on these could well see us in the mid 20s to low 30s.

LL,
Your dad was obviously a man of taste and refinement. Personally, I preferred Williams to Bream. Williams was calm and effortless whereas Bream was a little too manic for my liking. Bream was also a good lutenist (for the philistines - a lute player not a Luton town supporter).
Williams was the nearest thing to Segovia the greatest of all though they both studied under him. Segovia was the one who inspired me to take up guitar when I was 10.

C7,
Firstly, welcome back hope you are feeling good in mind and body.
I inadvertently stumbled on the TW piece. I started reading the biggest pile of garbage (apart from the TW piece a few years back) I have ever seen.
Then I got to...
"You have reached premium content"
"You must be a paid subscriber to see this page."
£5.99 per month to read that claptrap. I fell off the chair laughing.

LL,
It wasn’t meant as criticism of you at all. I just think that for proactive to publish an investment piece in August 2020 showing inflection points to come starting H1 2019 is diabolical.

LL,
I’m not sure about book marking the inflection points - they are very out of date.
If you add a year to MODI and two years to SCIB1 combo trial You may have something realistic.

Miavoce,
Possibly. We only have the title to go by at the moment, we will have to wait until the detail is published.

LL,
So I wonder why Scancell are pursuing a patent for Covidity?